Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback